AI-generated analysis. Always verify with the original filing.
Lunai Bioworks entered debt exchange agreements to convert $828,770 of notes into 3.9M common shares and warrants, and a binding agreement for $20M preferred stock investment to acquire BBB delivery technology for CNS Alzheimer’s assets.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement** On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectivel
Unregistered Sales of Equity Securities** ** ** The information set forth under the heading “Debt Exchange Agreements” in Item 1.01 of this Current Report on Fo
Other Events** ** ** On March 23, 2026, the Company’s board of directors approved the debt exchange transactions contemplated by the Debt Exchange Agreements an
Financial Statements and Exhibits. ** | Exhibit No. | Description | |---|---| | | | | 4.1 | Form of Common Stock Purchase Warrant | | 10.1 | Form of Exchange Ag
Material Agreement